XML 55 R30.htm IDEA: XBRL DOCUMENT v3.25.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash
The following table reconciles cash, cash equivalents and restricted cash reported within the Company's consolidated balance sheets to the total amounts reported in the consolidated statements of cash flows:                 
December 31,
Reconciliation of cash, cash equivalents and restricted cash (in thousands)202520242023
Cash and cash equivalents$184,844 $51,870 $42,925 
Restricted cash1,699 1,680 1,654 
Total cash, cash equivalents and restricted cash$186,543 $53,550 $44,579 
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash
The following table reconciles cash, cash equivalents and restricted cash reported within the Company's consolidated balance sheets to the total amounts reported in the consolidated statements of cash flows:                 
December 31,
Reconciliation of cash, cash equivalents and restricted cash (in thousands)202520242023
Cash and cash equivalents$184,844 $51,870 $42,925 
Restricted cash1,699 1,680 1,654 
Total cash, cash equivalents and restricted cash$186,543 $53,550 $44,579 
Schedule of Allowance for Credit Losses
The following table summarizes the activity related to the Company's allowance for credit losses (in thousands):
Year Ended December 31,
202520242023
Beginning balance$1,212 $1,029 $1,106 
Provision for bad debts1,479 877 (77)
Recoveries/(write-offs)— (695)— 
Ending balance$2,691 $1,212 $1,029 
Schedule of Revenue and Gross Accounts Receivable By Major Customer
Gross revenues and accounts receivable from each of the Company’s customers or collaboration partners who individually accounted for 10% or more of total gross revenues and/or 10% or more of total gross accounts receivable consisted of the following:
 
% of Total Gross Revenues
 Years Ended December 31,
Customer
202520242023
Fresenius Medical Care Rx30%48%40%
U.S. Renal Care29%**
DaVita, Inc.25%**
Cencora, Inc.*19%21%
McKesson Corporation*12%11%
Cardinal Health, Inc.**10%
 
 
% of Gross Accounts Receivable
 
December 31,
Customer
20252024
U.S. Renal Care42%*
DaVita, Inc.29%16%
Fresenius Medical Care Rx*42%
Cencora, Inc.*13%
*Percentage less than 10% threshold.
Schedule of Estimated Useful Lives for Property, Plant and Equipment Depreciation expense is recognized using the straight-line method over the estimated useful lives, which are typically:
Asset Category
Estimated Useful Life
Computer equipment and software3 years
Furniture and fixtures5 years-7 years
Laboratory and other equipment
7 years
Leasehold improvementsShorter of the useful life or remaining lease term